INDIANAPOLIS, Ind. - Eli Lilly and Company, a major pharmaceutical company, announced on Monday that its weight-loss drug, ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

Direct-to-consumer health startup Ro has partnered with Eli Lilly to provide more affordable ... loss drug Zepbound, streamlining access through a seamless platform. The initiative integrates ...

Michael Headrick says he’s lost 18 pounds since starting Zepbound injections about a month ago, with no noticeable side effects. (Photo courtesy of Adam Seif) Michael Headrick of Indianapolis ...

Zepbound generated $4.9 billion in global sales last year. Wegovy brought in nearly $8.8 billion (58.2 billlion Danish kroner). Access and affordability have limited wider use of the drugs.

CVS Health announced plans to drop Eli Lilly's Zepbound from its preferred coverage ... CVS said Caremark will offer Wegovy at "a more affordable price." As a pharmacy benefit manager, Caremark ...

Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide (brand name Wegovy) in a 72-week clinical trial. The randomized, controlled trial — called ...

A new study published in the New England Journal of Medicine comparing Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy — both approved to treat obesity — found that Zepbound is more ...

Zepbound generated $4.9 billion in global sales last year. Wegovy brought in nearly $8.8 billion. Access and affordability have limited wider use of the drugs. Tirzepatide and semaglutide were ...